Published

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: The New England journal of medicine
Date: 2022-11-03
Source: PubMed
DOI: 10.1056/nejmoa2206443
PubMed: 36322843

Derived topics and classifications

psilocybin Depression Clinical Trial Treatment-Resistant Depression Safety Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 20 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression2026-11-01 Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)2026-08-12 Cardiovascular safety of psilocybin in psychiatric practice: a narrative review2026-08-01 Pharmacokinetic and pharmacodynamic rational for expanding the therapeutic landscape of psilocybin beyond depression2026-08-01 Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysis2026-08-01 The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis2026-08-01 Longitudinal neural and psychological changes following psilocybin under compassion imagery priming2026-07-22 Silence is golden: Documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorder2026-07-16 Reporting practices in psilocybin-assisted therapy trials for depression: A descriptive review and temporal overview2026-07-13 CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder2026-07-07 Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility study2026-07-01 Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits2026-07-01 Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidence2026-07-01 An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive Disorder2026-07-01 Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in rats2026-07-01 Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants2026-07-01 Study Protocol for “Exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults”2026-06-30 Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex2026-06-28 DESI-MSI-Based Multi-Organ Distribution Mapping of Psilocin in Zebrafish2026-06-18 Efficacy of Psilocybin-Assisted Therapy in Major Depressive Disorder: A Systematic Review and Meta-Analysis2026-06-15

Related papers

Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2025-05-01 Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.American journal of therapeutics · 2024-01-01 A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.Journal of clinical psychopharmacology · 2022-01-01 Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term MeditatorsClinicalTrials.gov · 2014-05-20